Mar 14, 2002
NEW YORK (Reuters) - A former employee has accused drugmaker Warner-Lambert, acquired by Pfizer Inc. in 2000, of aggressively marketing the anticonvulsant Neurontin (gabapentin) to physicians for more than a dozen medical conditions for which it was not approved, the New York Times reported on Thursday.
David Franklin, a former research fellow at Harvard Medical School who was hired as a medical liaison by Warner-Lambert in 1996, alleges in court filings that the company was not satisfied with the limited sales potential of Neurontin.
To boost sales, the company illegally marketed Neurontin to physicians for conditions including attention deficit disorder in children, neurologic pain and bipolar disorder, Franklin said, according to the Times.
The US attorney's office in Boston is holding criminal and civil investigations into the marketing of Neurontin, the Times said, citing statements made by federal prosecutors in court.
Pfizer said it is cooperating with investigators and contesting the suit, which it does not expect to affect its finances significantly, the Times said.
Pfizer officials could not be reached early Thursday morning for further
© 2002 Reuters Ltd